Consistently, administration of the EGFR kinase inhibitor erlotinib (0.1-10 μM) and downstream MEK inhibitor PD 325901 (0.01-1 μM) dramatically reduced PDX-derived tumor cell cluster formation (Figure 1C and Figure S1C-D). This evidence concerns the gene MAP2K7 and neoplasm.